Bristol Myers Squibb (BMS) reported Q3 revenue of USD 12.2 billion with 3% growth, bringing the 9-month total to USD 35.7 billion despite 1% decline year-on-year (YoY) due to US market contraction offset by international expansion. Growth products included Opdivo (nivolumab), Breyanzi (lisocabtagene maraleucel) and Reblozyl (luspatercept) contributed USD 19.0 billion representing 17% increase, while legacy products Revlimid (lenalidomide) and Pomalyst (pomalidomide) declined 47% and 25% respectively. Opdivo revenue reached USD 7.4 billion with 8% growth supported by microsatellite instability-high colorectal cancer (MSI-H CRC) and first-line non-small cell lung cancer (NSCLC) share gains, alongside subcutaneous formulation Opdivo Qvantig generating USD 105 million.

CD19-directed CAR-T therapy Breyanzi achieved 100% growth to USD 966 million approaching blockbuster status, while erythroid maturation agent Reblozyl grew 35% to USD 1.7 billion in myelodysplastic syndrome (MDS) anaemia. Cardiovascular portfolio leader Eliquis (apixaban) contributed USD 11.0 billion, while myosin inhibitor Camzyos (mavacamten) increased 88% to USD 714 million. The recent USD 1.5-billion acquisition of Orbital Therapeutics added in vivo CAR-T platform OTX-201 to BMS's immuno-oncology pipeline. The company raised full-year guidance to USD 47.5 to 48.0 billion reflecting strong performance across growth products and pipeline advancements.

According to PharmCube's NextBiopharm® database, Breyanzi has enjoyed triple-digit growth since its launch. Click here to request a free trial for NextBiopharm®.